Loading...

Purified anti-mouse CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
10F.9G2 (See other available formats)
Regulatory Status
RUO
Other Names
B7-H1, PD-L1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
10Fdot9G2_Pure_081908.jpg
C57/B6 mouse splenocytes were stained with purified anti-CD274 (clone 10F.9G2) (pink line) or purified rat IgG2b, κ isotype control (green line), followed by biotinylated anti-rat IgG and Sav-PE
  • 10Fdot9G2_Pure_081908.jpg
    C57/B6 mouse splenocytes were stained with purified anti-CD274 (clone 10F.9G2) (pink line) or purified rat IgG2b, κ isotype control (green line), followed by biotinylated anti-rat IgG and Sav-PE
  • 10Fdot9G2_Pure_CD274_2_102518
    Fresh, frozen mouse spleen was stained with purified CD274 clone 10F.9G2 conjugated and detected with a Cy3 CODEX™ oligonucleotide duplex (red). Samples were counterstained with TCR FITC (greeb). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
Cat # Size Price Quantity Check Availability Save
124301 50 µg £37
Check Availability


Need larger quantities of this item?
Request Bulk Quote
124302 500 µg £97
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/mL
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F - Verified
Block - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Hirose T, et al. 2017. PLoS One. 12(6):e0178765. PubMed
  2. Speranza MC, et al. 2018. Neuro Oncol. 20:225. PubMed
  3. Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed
  4. Dieterich LC, et al. 2017. Front Immunol. 0.379166667. PubMed
  5. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  6. Giles DA, et al. 2018. J Clin Invest. 128:5322. PubMed
  7. Knier B, et al. 2018. Nat Immunol. 1.722916667. PubMed
  8. Mao W, et al. 2019. J Immunother Cancer. 0.484027778. PubMed
  9. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  10. Wang G, et al. 2020. Nat Commun. 11:1395. PubMed
  11. Yahata T, et al. 2019. Cancer Sci. 110:1279. PubMed
  12. Singh M, et al. 2017. Nat Commun. 8:1447. PubMed
  13. Jiao S, et al. 2020. Cell. 179(5):1177-1190.e13.. PubMed
  14. Meng Q, et al. 2006. Invest Ophthalmol Vis Sci. 47:4444. PubMed
  15. Scarlett U, et al. 2012. J Exp Med. 209:425. PubMed
  16. Bassi &, et al. 2012. Diabetes. 61:2534. PubMed
  17. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  18. Lei G, et al. 2015. Infect Immun . 83:572. PubMed
  19. Huang B, et al. 2015. PLoS One. 10: 0134715. PubMed
  20. Herold M, et al. 2015. J Immunol. 195: 3584 - 3595. PubMed
  21. Muhammad F, et al. 2020. Front Immunol. 975:11. PubMed
  22. Kong F, et al. 2021. Front Immunol. 12:670646. PubMed
  23. Hutton C, et al. 2021. Cancer Cell. 39:1227. PubMed
  24. Iida Y, et al. 2020. J Immunother Cancer. 8:. PubMed
  25. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  26. Schofield DJ, et al. 2021. MAbs. 13:1857100. PubMed
  27. Muhammad F, et al. 2020. J Autoimmun. 111:102441. PubMed
  28. Tan Z, et al. 2020. Mol Ther Oncolytics. 16:302. PubMed
  29. Zhao T, et al. 2022. JCI Insight. 7:. PubMed
  30. Sano Y, et al. 2021. Mol Cancer Res. 19:507. PubMed
  31. Iwai T, et al. 2021. Mol Cancer Ther. 20:2519. PubMed
  32. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  33. Lin A, et al. 2022. Bioeng Transl Med. 7:e10314. PubMed
  34. Li Z, et al. 2022. Transl Cancer Res. 11:3698. PubMed
  35. Liu CJ, et al. 2020. Neuro Oncol. 22:1276. PubMed
  36. Li H, et al. 2022. Cancer Cell. 40:36. PubMed
  37. Moore AR, et al. 2022. Cell Rep. 41:111651. PubMed
  38. Sun Y, et al. 2022. Mol Ther Oncolytics. 26:105. PubMed
  39. Peymanfar Y, et al. 2023. Int J Mol Sci. 24:. PubMed
RRID
AB_961226 (BioLegend Cat. No. 124301)
AB_961228 (BioLegend Cat. No. 124302)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 5    Revision Date: 01/08/2021

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account